In a recent study posted to the medRxiv* preprint server, researchers reported the findings of the phase 2a part of a phase 2/3 study that assessed the safety and efficacy of Ensitrelvir among patients with
Ensitrelvir demonstrates swift SARS-CoV-2 clearance and safety among individuals with asymptomatic, mild, or moderate SARS-CoV-2 infections
